高级检索
当前位置: 首页 > 详情页

Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Wuhan Institutes of Biomedical Sciences, School of Medicine, JianghanUniversity, Wuhan 430056, China [2]Guangdong Provincial Key Laboratoryof Liver Disease Research, The Third Affiliated Hospital, Sun Yat-sen University,Guangzhou 510620, China [3]Zhuhai Interventional Medical Center, ZhuhaiPrecision Medical Center, Zhuhai People’s Hospital, Zhuhai Hospital Affiliatedwith Jinan University, Zhuhai 519000, China [4]Jiangsu Key Laboratory of DrugScreening, Jiangsu Center for Pharmacodynamics Research and Evaluation,China Pharmaceutical University, Nanjing 2100 9, China [5]School of Pharmacy,Hubei University of Chinese Medicine, Wuhan 430065, China
出处:
ISSN:

关键词: Patient-derived model Patient-derived xenograft (PDX) Patient-derived organoid (PDO) Patient-derived cell (PDC) NCI-60

摘要:
As reported, preclinical animal models differ greatly from the human body. The evaluation model may be the colossal obstacle for scientific research and anticancer drug development. Therefore, it is essential to propose efficient evaluation systems similar to clinical practice for cancer research.While it has emerged for decades, the development of patient-derived xenografts, patient-derived organoid and patient-derived cell used to be limited. As the requirements for anticancer drug evaluation increases, patient-derived models developed rapidly recently, which is widely applied in basic research, drug development, and clinical application and achieved remarkable progress. However, there still lack systematic comparison and summarize reports for patient-derived models. In the current review, the development, applications, strengths, and challenges of patient-derived models in cancer research were characterized.Patient-derived models are an indispensable approach for cancer research and human health.© 2022. The Author(s).

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 3 区 外科 4 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学 3 区 外科
JCR分区:
出版当年[2020]版:
Q2 SURGERY Q4 ONCOLOGY
最新[2023]版:
Q1 SURGERY Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Wuhan Institutes of Biomedical Sciences, School of Medicine, JianghanUniversity, Wuhan 430056, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号